Study of ULSC for dermatomyositis and polymyositis
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This trial tests a new treatment called ULSC to see if it can improve muscle strength and skin symptoms, and help reduce steroid use in people with dermatomyositis or polymyositis. It may be an option if standard treatments haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with dermatomyositis or polymyositis by a doctor using standard criteria.
- You have active muscle weakness or skin rash, and signs of muscle inflammation from blood tests, MRI, or other tests.
- You are already taking at least one immune-suppressing medication or a low dose of steroids (like prednisone) that has been stable for at least 4 to 12 weeks.
- You have a specific antibody linked to myositis, or your doctor has ruled out other causes of symptoms.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during and for 3 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
This Phase 3 study tests whether interleukin-2 can better control “active” dermatomyositis, an inflammatory muscle and skin disease. Participants will be monitored to see if treatment improves disease activity and symptoms.
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
This trial is testing an investigational medicine called PF-08154225 for people with autoimmune diseases like rheumatoid arthritis, lupus, myositis, or systemic sclerosis. It aims to see if the drug is safe and effective in reducing disease activity.
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
This trial tests a new treatment using your own immune cells (CAR T-cells) targeted at a marker called CD19. It is for people whose lupus or myositis has not been controlled by other treatments.
Hear when a new Idiopathic Inflammatory Myositis (IIM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.